Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: AbbVie
Listed as NCT03874052, this PHASE1 trial focuses on Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Recurrent Acute Myeloid Leukemia and remains actively recruiting participants. Sponsored by AbbVie, it has been updated 16 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Jun 2025 — Sep 2025 [monthly]
Suspended PHASE1
-
Sep 2024 — Jun 2025 [monthly]
Suspended PHASE1
Status: Active Not Recruiting → Suspended
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 11 earlier versions
-
Oct 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — Apr 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Apr 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — Apr 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Incyte Corporation
- Jennifer Saultz
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .